Park Place Capital Corp Grows Stake in Sanofi (NASDAQ:SNY)

Park Place Capital Corp lifted its position in Sanofi (NASDAQ:SNY) by 6.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,068 shares of the company’s stock after buying an additional 534 shares during the period. Park Place Capital Corp’s holdings in Sanofi were worth $441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dynamic Advisor Solutions LLC purchased a new position in shares of Sanofi in the 4th quarter worth $2,104,000. Vestal Point Capital LP purchased a new position in Sanofi during the fourth quarter valued at $14,919,000. Oxbow Advisors LLC purchased a new position in Sanofi during the fourth quarter valued at $4,689,000. China Universal Asset Management Co. Ltd. lifted its position in Sanofi by 348.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 32,456 shares of the company’s stock valued at $1,614,000 after purchasing an additional 25,213 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Sanofi during the fourth quarter valued at $4,704,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

NASDAQ SNY opened at $49.59 on Tuesday. The company has a market capitalization of $125.60 billion, a PE ratio of 24.92, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The business’s fifty day moving average is $48.68 and its 200 day moving average is $48.57. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting the consensus estimate of $0.96. The company had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Sell-side analysts predict that Sanofi will post 4.13 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.